Personalis (PSNL) Stock Overview
Develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PSNL Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Personalis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.75 |
| 52 Week High | US$12.53 |
| 52 Week Low | US$3.84 |
| Beta | 2.28 |
| 1 Month Change | 38.49% |
| 3 Month Change | 34.30% |
| 1 Year Change | 49.31% |
| 3 Year Change | 375.61% |
| 5 Year Change | -62.77% |
| Change since IPO | -65.78% |
Recent News & Updates
Analysis Article • Jun 16
Personalis (PSNL) Stock Could Be 10% Undervalued After ASCO Cancer Data
Personalis (PSNL) stock is in focus after the company released new clinical data at the 2026 ASCO meeting, highlighting how its NeXT Personal test detects minimal residual disease across six solid tumor types. See our latest analysis for Personalis. The ASCO update comes after a sharp 53.93% 1 month share price return and a 37.50% 3 month share price return. The 1 year total shareholder return of 51.78% and very large 3 year total shareholder return indicate that momentum has been strong...
Narrative Update • Jun 04
PSNL: Ultrasensitive MRD Evidence And Expanded Coverage Will Support Balanced Future Outlook
Analysts have trimmed their price targets on Personalis by $1 to $2, citing updated assumptions for discount rates, profit margins, and long term P/E expectations. These revisions result in a slightly lower overall valuation outlook.Seeking Alpha • May 28
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating
Summary Personalis, Inc. is rated Buy, driven by strong momentum in its NeXT Personal Dx MRD test and recent Medicare coverage expansions. Despite a projected 2026 net loss of ~$100m and 14% revenue growth, PSNL's clinical test volume is ramping rapidly, with 43k–45k tests targeted this year. Key catalysts include expanded CMS MolDX coverage for breast and lung cancer recurrence monitoring and potential M&A interest given an $887m market cap. Risks include reliance on major pharma clients, a competitive MRD landscape, and the need to prove durable, scalable revenue growth amid ongoing losses. Read the full article on Seeking AlphaRecent updates
Analysis Article • Jun 16
Personalis (PSNL) Stock Could Be 10% Undervalued After ASCO Cancer Data
Personalis (PSNL) stock is in focus after the company released new clinical data at the 2026 ASCO meeting, highlighting how its NeXT Personal test detects minimal residual disease across six solid tumor types. See our latest analysis for Personalis. The ASCO update comes after a sharp 53.93% 1 month share price return and a 37.50% 3 month share price return. The 1 year total shareholder return of 51.78% and very large 3 year total shareholder return indicate that momentum has been strong...Narrative Update • Jun 04
PSNL: Ultrasensitive MRD Evidence And Expanded Coverage Will Support Balanced Future Outlook
Analysts have trimmed their price targets on Personalis by $1 to $2, citing updated assumptions for discount rates, profit margins, and long term P/E expectations. These revisions result in a slightly lower overall valuation outlook.Seeking Alpha • May 28
Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating
Summary Personalis, Inc. is rated Buy, driven by strong momentum in its NeXT Personal Dx MRD test and recent Medicare coverage expansions. Despite a projected 2026 net loss of ~$100m and 14% revenue growth, PSNL's clinical test volume is ramping rapidly, with 43k–45k tests targeted this year. Key catalysts include expanded CMS MolDX coverage for breast and lung cancer recurrence monitoring and potential M&A interest given an $887m market cap. Risks include reliance on major pharma clients, a competitive MRD landscape, and the need to prove durable, scalable revenue growth amid ongoing losses. Read the full article on Seeking AlphaNarrative Update • May 21
PSNL: Expanded Coverage And MRD Evidence Will Underpin Future Upside Potential
Analysts have nudged their average price target for Personalis lower by about $0.40. This reflects updated forecasts that factor in higher projected net losses and operating expenses in later years.Narrative Update • May 01
PSNL: Medicare Coverage And MRD Data Will Support Future Upside Potential
Analysts have trimmed their price target on Personalis to $10 from $11, citing updated views on longer term operating expenses and expected net losses. These updates also feed into a slightly higher discount rate and future P/E assumptions in current models.
Narrative Update • Apr 16
PSNL: Higher Spending And 2026 Loss Will Set Up Longer Term Upside Potential
Analysts now converge around a $10 price target for Personalis, reflecting updated views that incorporate expectations for higher outer year operating expenses and a wider 2026 net loss. Analyst Commentary Recent research updates point to a more cautious tone around Personalis, particularly as analysts factor in guidance for higher operating expenses and a wider 2026 net loss.Narrative Update • Apr 02
PSNL: Expanded Clinical Evidence And Coverage Will Support A Stronger Long Term Outlook
Analysts now center on a $10 price target for Personalis, citing updated loss expectations and higher longer term operating expense assumptions as key drivers of the shift from prior Street estimates. Analyst Commentary Bearish analysts are resetting expectations around Personalis, using the new $10 price target as a reference point for what they see as a more cautious risk and reward profile.
Narrative Update • Mar 19
PSNL: Medicare Coverage And MRD Data Will Reprice Future Risk Reward
Analysts have adjusted their view on Personalis, with price targets now ranging between $10 and $11 as they factor in updated expectations for future losses and operating expenses. Analyst Commentary Recent research updates on Personalis highlight a mix of cautious modeling changes and ongoing interest in the company’s longer term potential.Narrative Update • Mar 05
PSNL: Medicare Coverage Will Support Future Risk Reward Repricing
Narrative Update on Personalis The analyst price target on Personalis has moved from $13 to $13.00 as analysts factor in updated assumptions around revenue growth, profit margin and future P/E expectations. Analyst Commentary Bullish analysts have adjusted their price targets on Personalis, with one recent move taking the target to $13.00.Narrative Update • Feb 18
PSNL: Medicare Coverage And Refined Assumptions Will Support A Brighter Outlook
Analysts have increased their price target on Personalis by $1, citing updated views on fair value, slightly revised discount rate assumptions, and refreshed expectations for revenue growth, profit margin, and future P/E. Analyst Commentary Although the latest research includes a higher price target for Personalis, the tone around the stock remains measured.Narrative Update • Feb 04
PSNL: Medicare Coverage For Cancer Surveillance Will Reshape Future Risk Reward Profile
Analysts have increased their fair value estimate for Personalis from US$9.00 to US$13.00, citing updated assumptions around revenue growth, profit margins, and future P/E. They have also incorporated recent Street research that reflected Medicare coverage news and refreshed price targets.Narrative Update • Jan 21
PSNL: Medicare Coverage Will Shape Future Upside Despite Biopharma Headwinds
Narrative update on Personalis Analysts have lifted their blended price expectations for Personalis toward the US$9 to US$11 range, citing recent Medicare coverage for the NeXT Personal test and Q3 revenue that came in above guidance as key supports for the higher targets. Analyst Commentary Recent Street research on Personalis has focused on two main developments: Medicare coverage for the NeXT Personal test in breast cancer surveillance, and Q3 revenue that came in ahead of the guided range, internal estimates, and consensus.Analysis Article • Jan 17
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Personalis, Inc. ( NASDAQ:PSNL ) shares have had a really impressive month, gaining 28% after a shaky period...Narrative Update • Jan 07
PSNL: Medicare Coverage And Biopharma Headwinds Will Shape A Balanced Outlook
Analysts lifted their projected fair value for Personalis, citing recent price target increases to $9 and $11, and pointing to Medicare coverage for the NeXT Personal test and reimbursement trends as key supports for their updated view. Analyst Commentary Recent research takes a mixed view on Personalis, with price targets being adjusted around specific catalysts such as Medicare coverage for NeXT Personal and reported Q3 revenue.Narrative Update • Dec 23
PSNL: Medicare Coverage Will Drive Reimbursement Momentum And Support A Higher Share Price
Analysts have raised their price target on Personalis significantly, from about $5 to a range centered near $10 per share, citing stronger revenue growth expectations, improving profit margins, and increased confidence in long-term reimbursement trends. Analyst Commentary Recent target price revisions reflect a more constructive outlook on Personalis as reimbursement visibility improves and revenue trends modestly outperform prior expectations.Narrative Update • Dec 09
PSNL: Medicare Reimbursement Will Drive Future Momentum Despite Biopharma Guidance Headwinds
Analysts have modestly raised their price target on Personalis, citing stronger-than-expected Q3 revenue and expanding reimbursement visibility. Their estimate of fair value has edged up from roughly $10.71 to $11.00 per share.Narrative Update • Nov 24
PSNL: Medicare Coverage Will Support Momentum Despite Guidance Headwinds
Narrative Update on Personalis Analysts have raised their price target for Personalis from approximately $8.50 to $10.71 per share. They cite recent Medicare coverage for the NeXT Personal test and stronger-than-expected quarterly revenue as supporting factors for the upward revision.Narrative Update • Nov 08
PSNL: Reimbursement Progress Will Drive Momentum Despite Guidance Reduction
Analysts have raised their fair value estimate for Personalis from $8.06 to $8.50 per share. They cite stronger revenue growth prospects and continued progress on reimbursement as key factors behind the upgrade.Analysis Article • Nov 07
Personalis, Inc. (NASDAQ:PSNL) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.50
Personalis, Inc. ( NASDAQ:PSNL ) just released its quarterly report and things are looking bullish. Revenues beat...Analysis Article • Oct 31
Personalis, Inc.'s (NASDAQ:PSNL) P/S Is Still On The Mark Following 46% Share Price Bounce
Despite an already strong run, Personalis, Inc. ( NASDAQ:PSNL ) shares have been powering on, with a gain of 46% in the...Narrative Update • Oct 25
Clinical Testing Progress And Medicare Coverage Will Influence Share Momentum Ahead
Analysts have revised Personalis's price target downward from $8.00 to $6.00. They cite weaker than expected pharma order timing and softer profit projections, despite continued progress in clinical testing and Medicare coverage goals.Analysis Article • Sep 16
Revenues Tell The Story For Personalis, Inc. (NASDAQ:PSNL) As Its Stock Soars 29%
Personalis, Inc. ( NASDAQ:PSNL ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...Analysis Article • Sep 10
Is Personalis (NASDAQ:PSNL) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Aug 10
These Analysts Think Personalis, Inc.'s (NASDAQ:PSNL) Sales Are Under Threat
Today is shaping up negative for Personalis, Inc. ( NASDAQ:PSNL ) shareholders, with the analysts delivering a...Analysis Article • Aug 02
Personalis, Inc. (NASDAQ:PSNL) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing
The Personalis, Inc. ( NASDAQ:PSNL ) share price has softened a substantial 28% over the previous 30 days, handing back...Analysis Article • May 06
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 37% But Its P/S Still Looks Reasonable
Personalis, Inc. ( NASDAQ:PSNL ) shareholders are no doubt pleased to see that the share price has bounced 37% in the...
New Narrative • Mar 30
NeXT Personal Testing And Moderna Partnership Will Improve Cancer Care
Strategic partnerships and agreements are expected to drive significant revenue and market expansion, particularly in MRD testing and tumor profiling.Analysis Article • Mar 21
What You Can Learn From Personalis, Inc.'s (NASDAQ:PSNL) P/S After Its 40% Share Price Crash
Personalis, Inc. ( NASDAQ:PSNL ) shareholders that were waiting for something to happen have been dealt a blow with a...Analysis Article • Mar 02
Personalis, Inc. (NASDAQ:PSNL) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a sad week for Personalis, Inc. ( NASDAQ:PSNL ), who've watched their investment drop 12% to US$4.14 in the...Analysis Article • Feb 04
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Personalis, Inc. ( NASDAQ:PSNL ) shares have had a horrible month, losing 26% after a relatively good period...Analysis Article • Nov 19
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Personalis, Inc. ( NASDAQ:PSNL ) share price has dived 26% in the last thirty...Seeking Alpha • Oct 28
The Proper Play On Personalis
Summary Today, we revisit the diagnostic concern of Personalis, Inc. The company recently expanded its partnership with Tempus AI and is seeing lower quarterly losses. The company has a solid balance sheet, strong analyst support, and is seeing revenue growth in a large and growing market. An updated analysis around Personalis follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • Sep 14
Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump
Personalis, Inc. ( NASDAQ:PSNL ) shares have continued their recent momentum with a 28% gain in the last month alone...Analysis Article • Jul 25
A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb
Personalis, Inc. ( NASDAQ:PSNL ) shareholders have had their patience rewarded with a 131% share price jump in the last...Analysis Article • Apr 19
Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower
Personalis, Inc. ( NASDAQ:PSNL ) shares have had a horrible month, losing 25% after a relatively good period...Analysis Article • Mar 02
Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story
Personalis, Inc. ( NASDAQ:PSNL ) shareholders would be excited to see that the share price has had a great month...Analysis Article • Dec 18
Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story
Personalis, Inc. ( NASDAQ:PSNL ) shareholders would be excited to see that the share price has had a great month...Analysis Article • Dec 04
Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Shareholder Returns
| PSNL | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 3.5% | -3.2% | 2.0% |
| 1Y | 49.3% | 9.1% | 23.3% |
Return vs Industry: PSNL exceeded the US Life Sciences industry which returned 11.4% over the past year.
Return vs Market: PSNL exceeded the US Market which returned 25.5% over the past year.
Price Volatility
| PSNL volatility | |
|---|---|
| PSNL Average Weekly Movement | 12.2% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PSNL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PSNL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 260 | Chris Hall | www.personalis.com |
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient.
Personalis, Inc. Fundamentals Summary
| PSNL fundamental statistics | |
|---|---|
| Market cap | US$1.02b |
| Earnings (TTM) | -US$95.55m |
| Revenue (TTM) | US$64.52m |
15.8x
P/S Ratio-10.7x
P/E RatioIs PSNL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSNL income statement (TTM) | |
|---|---|
| Revenue | US$64.52m |
| Cost of Revenue | US$55.66m |
| Gross Profit | US$8.85m |
| Other Expenses | US$104.40m |
| Earnings | -US$95.55m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 13.72% |
| Net Profit Margin | -148.11% |
| Debt/Equity Ratio | 0.3% |
How did PSNL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/18 15:18 |
| End of Day Share Price | 2026/06/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Personalis, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Derik de Bruin | BofA Global Research |
| Mark Massaro | BTIG |
| Patrick Donnelly | Citigroup Inc |